← All indications
Hypertension, Pulmonary
Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
Subtype terms (3)
More specific conditions that are subtypes of Hypertension, Pulmonary in the MeSH hierarchy.
- Familial Primary Pulmonary Hypertension
23 drugs (19 approved, 4 experimental)
- Persistent Fetal Circulation Syndrome
10 drugs (9 approved, 1 experimental)
- Pulmonary Arterial Hypertension
114 drugs (67 approved, 47 experimental)
Drugs by status
Approved for this indication (10)
Phase 4 trials (20)
Phase 3 trials (27)
Phase 2 trials (62)
- nitrous oxide
- simvastatin
- metformin
- sodium nitrite
- hymecromone
- amyl nitrite
- autologous epcs transfected with human enos
- beetroot juice
- mirabegron
- capsaicin
- cxa-10
- bq-123
- empagliflozin
- l-glutamine
- gsk2586881
- hydroxyurea
- helium-3
- xenon-129
- iron dextran
- ketone
- nx1011
- pf-00489791
- atorvastatin
- magnesium sulfate
- prx08066
- adrenomedullin (22-52)
- red blood cells
- immune globulin (human)
- semaglutide
- sirolimus
- +32 more
Phase 1 trials (39)
- nitroglycerin
- 99mtc-pulmobind
- vitamin e
- theophylline
- bambuterol
- epoetin
- captopril
- norepinephrine
- alpha-lipoic acid
- sodium dichloroacetate
- dimethyl fumarate
- fexofenadine
- gsk2256098
- hyperpolarized helium
- acetylcholine chloride
- artesunate
- gadopenteate dimeglumine
- mk-8892
- nitroprusside
- vitamin c
- phentolamine mesylate
- lidocaine
- enos transfected epcs
- albuterol
- nitric acid
- chlorhexidine
- esomeprazole
- l-nmma
- reserpine
- aminophylline
- +9 more
Organizations
Organization Involved with Phase 4 Indications (64)
- Eli Lilly
- GlaxoSmithKline
- Mallinckrodt
- National Institutes of Health (NIH)
- National Center for Research Resources (NCRR)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of General Medical Sciences (NIGMS)
- Dr. Robert Klempfner Heart Rehabilitation Institute
- Aarhus University
- University of Arizona
- Baylor University
- Boston University
- Chronic Obstructive Pulmonary Disease Trial Network, Denmark
- University of London
- Duke University
- Hospital General Universitario Gregorio Marañon
- Johns Hopkins University
- Northwell Health
- Northwestern University
- Ochsner Health System
- Sir Takhtasinhji General Hospital
- Stanford University
- Shengjing Hospital
- Tanta University
- University of Florida
- University of Kentucky
- University of Ottawa
- University of Pavia
- University of Rochester
- University of Southern California
- +34 more
Organization Involved with Phase 3 Indications (96)
- Asklepion
- Encysive
- Mitsubishi
- Merck
- ICOS
- Arena Pharmaceuticals
- Dong-A Pharmaceutical
- EPS Corporation
- Hamad Medical Corporation
- Hamilton Health Sciences Corporation
- Hannover Clinical Trial Center GmbH
- Liquidia Technologies, Inc.
- Lung Biotechnology PBC
- Reata Pharmaceuticals, Inc.
- SciPharm SàRL
- Center for Health, Exercise and Sport Sciences, Serbia
- Huazhong University of Science and Technology
- University of Pennsylvania
- University of Pittsburgh
- Ain Shams University
- Alexandria University
- Baskent University
- Brown University
- Case Western Reserve University
- Cornell University
- Harvard University
- Emory University
- University of Washington
- Gottfried Wilhelm Leibniz Universität Hannover
- Guangzhou Medical University
- +66 more
Organization Involved with Phase 2 Indications (57)
- Epix Pharmaceuticals
- Organon
- Roche
- Bracco
- NITROX, LLC
- Northern Therapeutics
- Boehringer Ingelheim
- Tenax Therapeutics, Inc.
- Medical Research Council
- National Institute on Aging (NIA)
- Advent Health
- Georgetown University
- Instituto Mexicano del Seguro Social
- Liaocheng People's Hospital
- NHS Fife
- Ohio State University
- Rhode Island Hospital
- RTI International
- Universidad Complutense de Madrid
- University of Dundee
- University of Heidelberg
- University of Maryland
- University of Alberta
- Virginia Commonwealth University
- Assiut University
- Columbia University
- General Hospital of Chalkida
- Sohag University
- University of Utah
- University of Minnesota
- +27 more
Organization Involved with Phase 1 Indications (20)
- PPD
- Aires Pharmaceuticals, Inc.
- Biogen
- Parexel
- Aadi, LLC
- The EMMES Corporation
- Hebei University
- Arizona State University
- Lakehead University
- Loma Linda University
- Osaka University
- University of Kansas
- University of Oklahoma
- University of Oregon
- Hammersmith Medicines Research
- Covance
- Norwegian Military
- University of Texas, Galveston
- University of Western Ontario
- Northern Ontario School of Medicine
Organization Involved with Other Experimental Indications (23)
- Astellas
- Fundación Neumologica Colombiana
- Medical University of Graz
- Instituto Nacional de Cardiologia Ignacio Chavez
- Lund University
- Marywood University
- NHS Lothian
- Cayetano Heredia University
- University of Glasgow
- University of South Florida
- Aga Khan University
- University of Copenhagen
- National Taiwan University
- Government of Pakistan
- Aretaieion University
- American Medical Association
- Bedford Pharmaceuticals
- Centura Health
- Universidad de la Sabana
- Pulmodyne, Inc.
- Stem Medicina Regenerativa
- Himalayan Rescue Association
- CryoHoldco LATAM